Beam Therapeutics Inc. (NASDAQ: BEAM) announced updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE